PSA
56
5
VMC
59
3
VIX
22
-2
SHW
59
3
EBAY
49
-3
TXN
69
4
GS
72
2
HBAN
79
5
ED
34
-2
FRT
58
2
INTU
53
2
AMG
77
2
FIS
58
-2
WDC
61
-3
T
35
-3
ITW
40
3
CCL
58
3
SLB
44
5
NWSA
64
4
VFC
74
3
PSA
56
5
VMC
59
3
VIX
22
-2
SHW
59
3
EBAY
49
-3
TXN
69
4
GS
72
2
HBAN
79
5
ED
34
-2
FRT
58
2
INTU
53
2
AMG
77
2
FIS
58
-2
WDC
61
-3
T
35
-3
ITW
40
3
CCL
58
3
SLB
44
5
NWSA
64
4
VFC
74
3
Financhill
Back

Relay Therapeutics, Inc. 10K Form

Buy
59

RLAY
Relay Therapeutics, Inc.

Last Price:
$8.01
Seasonality Move:
-10.52%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RLAY News And Ratings

See the #1 stock for the next 7 days that we like better than RLAY

RLAY Financial Statistics

Sales & Book Value

Annual Sales: $10M
Cash Flow: $-62.1M
Price / Cash Flow: 0
Annual Sales: $3.52
Price / Book: 2.23

Profitability

EPS (TTM): -1.75060
Net Income (TTM): $-297.6M
Gross Margin: $4.5M
Return on Equity: -41.21%
Return on Assets: -37.2%

Relay Therapeutics, Inc. Earnings Forecast

Key Relay Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 7 years for RLAY is 45.40%.
  • The Selling, General & Administrative Expenses for RLAY have been equal to 765.38% of Gross Profit Margin.
  • The Research & Development expenses have been 3,188.66% of Revenue.
  • The Net Earning history of RLAY is -3,374.72% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

Relay Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RLAY
CUSIP: 75943R
Website: relaytx.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 19.14
Quick Ratio: 18.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RLAY Technical Analysis vs Fundamental Analysis

Buy
59
Relay Therapeutics, Inc. (RLAY) is a Buy

Is Relay Therapeutics, Inc. a Buy or a Sell?